Rosenstock J, Frias J, Jastreboff AM et al (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
TB500 promotes cell migration, cytoskeletal reorganization, and new blood vessel formation in preclinical modelskey steps in early wound healing and longterm tissue remodeling
Why people use it: Longevity biohackers have latched onto Epitalon as an anti-aging therapy, largely because of its purported ability to support our telomeres
Consult with your healthcare provider and consider legal options if youve experienced adverse effects